ES2104121T3 - Variante de un inhibidor de proteasas, de tipo kunitz, de origen humano. - Google Patents

Variante de un inhibidor de proteasas, de tipo kunitz, de origen humano.

Info

Publication number
ES2104121T3
ES2104121T3 ES93902105T ES93902105T ES2104121T3 ES 2104121 T3 ES2104121 T3 ES 2104121T3 ES 93902105 T ES93902105 T ES 93902105T ES 93902105 T ES93902105 T ES 93902105T ES 2104121 T3 ES2104121 T3 ES 2104121T3
Authority
ES
Spain
Prior art keywords
cys
variant
glu
amino acid
phe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93902105T
Other languages
English (en)
Inventor
Fanny Norris
Kjeld Norris
Soren Erik Bjorn
Lars Christian Petersen
Ole Hvilsted Olsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of ES2104121T3 publication Critical patent/ES2104121T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Prostheses (AREA)
  • Amplifiers (AREA)

Abstract

UNA VARIANTE DEL CAMPO INHIBIDOR DE PROTEASA DE TIPO KUNITZ HUMANO II DE INHIBIDOR DE PASO DE FACTOR DE TEJIDO (TFPI), COMPRENDIENDO LA VARIANTE LA SIGUIENTE SECUENCIA AMINOACIDA X1 ASP PHE CYS PHE GLU GLU ASP X2 GLY X3 CYS X4 X5 X6 X7 X8 X9 TYR PHE TYR ASN AS GLN THR LYS GLN CYS GLU ARG PHE X10 TYR GLY GLY CYS X11 X12 X13 MET ASN PHE X14 THR LEU GLU GLU CYS -LYS ASN ILE CYS GLU ASP X15(SEQ ID NO 1) EN LA QUE X1 REPRESENTA H O 1-5 RESIDUOS AMINOACIDOS PRODUCIDOS NATURALMENTE EXCEPTO CYS, X2-X14 CADA UNO INDEPENDIENTEMENTE REPRESENTA UN RESIDUO AMINOACIDO PRODUCIDO NATURALMENTE, Y X15 REPRESENTA OH, O 1-5 RESIDUOS AMINOACIDOS PRODUCIDOS NATURALMENTE EXCEPTO CYS, SIEMPRE QUE UNO DE LOS RESIDUOS AMINOACIDOS X1-X15 SEA DIFERENTE DEL RESIDUO AMINOACIDO CORRESPONDIENTE DE LA SECUENCIA NATIVA.
ES93902105T 1992-01-07 1993-01-07 Variante de un inhibidor de proteasas, de tipo kunitz, de origen humano. Expired - Lifetime ES2104121T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK9200001 1992-01-07

Publications (1)

Publication Number Publication Date
ES2104121T3 true ES2104121T3 (es) 1997-10-01

Family

ID=8153770

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93902105T Expired - Lifetime ES2104121T3 (es) 1992-01-07 1993-01-07 Variante de un inhibidor de proteasas, de tipo kunitz, de origen humano.

Country Status (18)

Country Link
US (1) US5576294A (es)
EP (1) EP0621871B1 (es)
JP (1) JP3350549B2 (es)
KR (1) KR100278036B1 (es)
AT (1) ATE154938T1 (es)
AU (1) AU676145B2 (es)
CA (1) CA2127249A1 (es)
CZ (1) CZ284911B6 (es)
DE (1) DE69311893T2 (es)
ES (1) ES2104121T3 (es)
FI (1) FI943233A0 (es)
HU (1) HU218104B (es)
IL (1) IL104325A (es)
NO (1) NO942550L (es)
NZ (1) NZ246569A (es)
PL (1) PL175422B1 (es)
WO (1) WO1993014121A1 (es)
ZA (1) ZA9395B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060134087A1 (en) * 1988-09-02 2006-06-22 Dyax Corp. ITI-D1 Kunitz domain mutants as hNE inhibitors
US5455338A (en) * 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
EP0737207B1 (en) 1994-01-11 2004-09-22 Dyax Corporation Inhibitors of human plasmin derived from the kunitz domains
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
CA2180950C (en) * 1994-01-11 2005-03-29 William Markland Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
US5795954A (en) * 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
US5589359A (en) 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
AU707762B2 (en) * 1994-08-05 1999-07-22 Novartis Vaccines And Diagnostics, Inc. Production of tissue factor pathway inhibitor
US5780265A (en) * 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
US5786328A (en) * 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US20030199450A1 (en) * 2001-04-27 2003-10-23 Chiron Corporation Regulation of cytokine synthesis and release
US6242414B1 (en) 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
WO1997033996A2 (en) * 1996-03-11 1997-09-18 Bayer Corporation Human bikunin
US20070140979A1 (en) * 1998-12-22 2007-06-21 Bayer Aktiengesellschaft Method for accelerating the rate of mucociliary clearance
ATE254473T1 (de) * 1998-12-22 2003-12-15 Bayer Ag Verwendung eines serinproteaseinhibitors vom kunitz-typ zur beschleunigung der schleimauflöserate
GB9916913D0 (en) * 1999-07-19 1999-09-22 Natural Enviromental Research Inhibitor proteins
US20040054082A1 (en) * 2001-12-03 2004-03-18 Bank David H Toughened polymer blends with improved surface properties
PT2298278E (pt) 2002-06-07 2016-02-25 Dyax Corp Prevenção e redução da perda de sangue e resposta inflamatória
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
WO2004019968A1 (en) * 2002-08-28 2004-03-11 Dyax Corp. Methods for preserving organs and tissues
PT1587907E (pt) * 2003-01-07 2011-04-08 Dyax Corp Biblioteca de domínios de kunitz
US6989369B2 (en) 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
CA3050564A1 (en) * 2003-08-29 2005-03-10 Dyax Corp. Poly-pegylated protease inhibitors
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
US20070213275A1 (en) * 2006-03-10 2007-09-13 Dyax Corp. Formulations for ecallantide
EP2379096B1 (en) 2008-12-19 2019-10-30 Baxalta GmbH Tfpi inhibitors and methods of use
JP2013516389A (ja) 2009-01-06 2013-05-13 ダイアックス コーポレーション カリクレイン阻害剤による粘膜炎治療
CN101798346B (zh) * 2009-02-06 2013-05-29 复旦大学 一种酵母表达的长效重组人组织因子途径抑制物
ES2905545T3 (es) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
ES2983470T3 (es) 2010-03-19 2024-10-23 Takeda Pharmaceuticals Co Inhibidores del TFPI y métodos de uso
KR102011156B1 (ko) 2011-01-06 2019-08-16 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
KR101391988B1 (ko) 2011-11-04 2014-05-08 동아대학교 산학협력단 항섬유소용해 기능을 가진 호박벌 독액의 쿠니츠 타입 세린 프로테아제 저해 폴리펩티드 및 이를 코딩하는 염기서열
BR112014022435B1 (pt) 2012-03-21 2023-02-14 Takeda Pharmaceutical Company Limited Inibidores de tfpi e métodos de uso
IL247942B (en) 2014-03-27 2022-09-01 Dyax Corp Compositions and methods for drops in macular edema as a result of diabetes
US11286307B2 (en) 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
AU2021209045A1 (en) 2020-01-13 2022-07-28 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
DK408089D0 (da) * 1989-08-18 1989-08-18 Novo Nordisk As Proteiner

Also Published As

Publication number Publication date
DE69311893D1 (de) 1997-08-07
EP0621871A1 (en) 1994-11-02
CZ164994A3 (en) 1994-12-15
JP3350549B2 (ja) 2002-11-25
CZ284911B6 (cs) 1999-04-14
PL175422B1 (pl) 1998-12-31
KR940703854A (ko) 1994-12-12
HU9401991D0 (en) 1994-09-28
HU218104B (hu) 2000-06-28
DE69311893T2 (de) 1998-02-05
IL104325A0 (en) 1993-05-13
ZA9395B (en) 1993-08-20
NO942550D0 (no) 1994-07-06
FI943233A7 (fi) 1994-07-06
HUT70295A (en) 1995-09-28
NO942550L (no) 1994-09-07
NZ246569A (en) 1996-05-28
CA2127249A1 (en) 1993-07-22
EP0621871B1 (en) 1997-07-02
ATE154938T1 (de) 1997-07-15
US5576294A (en) 1996-11-19
FI943233L (fi) 1994-07-06
IL104325A (en) 2000-10-31
AU3345993A (en) 1993-08-03
AU676145B2 (en) 1997-03-06
KR100278036B1 (ko) 2001-01-15
FI943233A0 (fi) 1994-07-06
WO1993014121A1 (en) 1993-07-22
JPH07506335A (ja) 1995-07-13

Similar Documents

Publication Publication Date Title
NO942552L (no) Humanproteaseinhibitorvarianter av Kunitz-type
NO942550L (no) Humanproteaseinhibitorvariant av Kunitz-type
NO942549L (no) Humanproteaseinhibitorvariant av Kunitz-type
NO942551L (no) Humanproteaseinhibitorvariant av Kunitz-type
DE68928810D1 (de) Analoge vom menschlichen Insulin
RO91186B (ro) Procedeu pentru prepararea unor peptide cu actiune asupra functiei glandei pituitare
ES2041611T1 (es) Un pentapeptido ciclico y su procedimiento de preparacion.
NO942553D0 (no) Ny humanproteaseinhibitor av Kunitz-type og varianter derav
AR006517A1 (es) Polipeptido que alcanza un total de alrededor de 30 aminoacidos; sustancia, peptidomimetico y composicion farmaceutica resultantes; usos del polipeptidoy proceso para la sintesis del polipeptido.
YU45587B (sh) Postupak za dobijanje grf analoga
Gagnon et al. Primary structure of the A chain of human complement-classical-pathway enzyme C1r. N-terminal sequences and alignment of autolytic fragments and CNBr-cleavage peptides
DK137085D0 (da) Fremgangsmaade og mellemprodukter til fremstilling af racematfattigepeptider
YU64192A (sh) Analozi insulina
ES2119746T3 (es) Nuevo peptido fisiologicamente activo y agente regulador del metabolismo del calcio que comprende dicho peptido como ingrediente activo.
TH2482B (th) สารคล้ายคลึง จี อาร์ เอฟ (grf)
FR2787454B1 (fr) Inhibiteur de la topoisomerase ii
ATE388965T1 (de) Menschliche antithrombin-varianten
TH1653A (th) Grf ของตับอ่อนของคน
SE8006333L (sv) Polypeptid psp och salter derav
TH1778A (th) สารคล้ายคลึง จี อาร์ เอฟ (grf)
RU94036770A (ru) Домен ингибитора протеазы, днк, вектор, клетка, способ получения домена, фармацевтическая композиция, применение домена

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 621871

Country of ref document: ES